KYMR

Latest SEC Filings & News for KYMR

1 most recent filing and news item mentioning KYMR. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/KYMR/news?limit=20"

Pull KYMR filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day
GuidanceJun 25, 2026Positive

Kymera completes Phase 2b enrollment for atopic dermatitis candidate KT-621

Kymera finished enrollment early for the Phase 2b BROADEN2 trial for atopic dermatitis candidate KT-621, accelerating data timelines to year-end 2026. The early success supports the company's plan to initiate Phase 3 trials in mid-2027 following regulatory review.

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.